9.15
Studi di bioequivalenza: biowaivers
In alcuni casi, i test di dissoluzione in vitro possono sostituire gli studi di bioequivalenza in vivo. Ciò è particolarmente vero quando un medicinal…
In determinate condizioni, i test di dissoluzione in vitro possono essere utilizzati al posto degli studi di bioequivalenza in vivo.
Quando un farmaco ha lo stesso rapporto di ingredienti attivi e inattivi in tutti i dosaggi, è possibile rinunciare ai test di bioequivalenza in vivo per i dosaggi più bassi, a condizione che il dosaggio più elevato superi i test di dissoluzione e in vivo .
I test di dissoluzione comparativa sono adeguati per indicare la bioequivalenza quando esiste una forte correlazione tra la dissoluzione di un farmaco e la biodisponibilità.
La maggior parte dei farmaci, come le compresse e le capsule a rilascio immediato, mancano di tale correlazione e richiedono studi in vivo per stabilire la bioequivalenza del dosaggio più elevato.
Se i prodotti a dosaggio più basso mostrano somiglianze nei principi attivi e inattivi, può essere necessaria solo una dissoluzione comparativa in vitro .
La FDA consente di derogare agli studi di bioequivalenza per i prodotti in cui è evidente, come le soluzioni per uso parenterale, orale o locale, a condizione che abbiano rapporti identici di ingredienti attivi e inattivi dei prodotti di riferimento.
View the full transcript and gain access to JoVE Core videos
Q1: When can in vitro dissolution tests replace in vivo bioequivalence studies?
In vitro dissolution tests can replace in vivo bioequivalence studies when a strong correlation exists between a drug's dissolution and bioavailability. Additionally, the FDA permits waiving bioequivalence studies for products where bioequivalence is self-evident, such as solutions for parenteral, oral, or local use, provided they have identical ratios of active and inactive ingredients as reference products.
Q2: What conditions allow bioequivalence testing to be waived for lower-strength drug products?
Bioequivalence testing for lower-strength products can be waived when the drug maintains proportional similarity in active and inactive ingredients across all strengths, provided the highest strength passes both dissolution and in vivo bioequivalence tests. If lower-dose-strength products demonstrate substantial similarity in composition, comparative in vitro dissolution may suffice instead of full bioequivalence studies.
Q3: Why do most immediate-release tablets and capsules require in vivo bioequivalence studies?
Most immediate-release tablets and capsules lack a strong correlation between dissolution and bioavailability, making in vitro dissolution tests inadequate to establish bioequivalence. Therefore, in vivo bioequivalence studies are necessary to demonstrate that these drug products achieve comparable systemic exposure and therapeutic effects as reference formulations.
Q4: What is the minimum bioequivalence study requirement for oral solid dosage forms seeking biowaivers?
For oral solid dosage forms, at least one dose strength, typically the highest strength, must be supported by an acceptable in vivo bioequivalence study. Once the highest strength demonstrates bioequivalence, lower-strength variants may qualify for biowaivers if they meet proportional similarity and acceptable in vitro dissolution criteria.
Q5: Are generic modified-release products eligible for bioequivalence biowaivers?
No, generic modified-release products are generally ineligible for biowaivers. These formulations require full bioequivalence studies because their complex release mechanisms and absorption profiles cannot be reliably predicted from in vitro dissolution data alone, necessitating in vivo evaluation to ensure therapeutic equivalence.
Q6: What specific criteria must be met to grant biowaivers to non-biostudy strengths of generic immediate-release drugs?
To grant biowaivers to non-biostudy strengths of generic immediate-release solid oral dosage forms, the FDA requires conducting an acceptable bioequivalence study on at least one strength, demonstrating proportional similarity in active and inactive ingredients, and providing acceptable in vitro dissolution data for the strength seeking the biowaiver.
Q7: How does proportional similarity in drug composition affect biowaiver eligibility?
When a drug product maintains the same ratio of active and inactive ingredients across all strengths, proportional similarity is established. This similarity is a key criterion for biowaiver eligibility, allowing lower strengths to avoid full bioequivalence testing if the highest strength passes required dissolution and in vivo studies.